Market Place
Sourcing Support
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
10 Jun 2025 //
GLOBENEWSWIRE
MiNK Therapeutics Gets NIAID Grant for Allo-iNKT Cell Therapy
02 Jun 2025 //
GLOBENEWSWIRE
MiNK Therapeutics Reports Q1 2025 Results and Progress
15 May 2025 //
GLOBENEWSWIRE
MiNK Therapeutics Corporate Update and Q1 2025 Financial Report
05 May 2025 //
GLOBENEWSWIRE
MiNK Therapeutics Reports Q4 & Full Year 2024 Results & Business
18 Mar 2025 //
GLOBENEWSWIRE
MiNK To Provide Q4, Full-Year 2024 Financial, Corporate Update
04 Mar 2025 //
GLOBENEWSWIRE
MiNK Therapeutics Presents Allo-iNKTs Data at AACR IO Meeting
24 Feb 2025 //
GLOBENEWSWIRE
MiNK Therapeutics Regains Nasdaq Listing Compliance
20 Feb 2025 //
GLOBENEWSWIRE
MiNK Therapeutics Presents Phase 2 Data on AgenT-797
12 Feb 2025 //
GLOBENEWSWIRE
MiNK Combines Allo-iNKTs Plus BOT/BAL For Gastroesophageal Cancers
23 Jan 2025 //
GLOBENEWSWIRE
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer
18 Dec 2024 //
GLOBENEWSWIRE
MiNK Therapeutics Reports Q3 2024 Results & Business Update
14 Nov 2024 //
GLOBENEWSWIRE
MiNK Therapeutics to Provide Corporate Update & Q3 Financial Report
11 Nov 2024 //
GLOBENEWSWIRE
MiNK’s iNKT Cell Therapy Shows Promise at SITC 2024
07 Nov 2024 //
GLOBENEWSWIRE
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board
31 Oct 2024 //
GLOBENEWSWIRE
MiNK And Autonomous Partner On Metastatic Tumor Therapies
08 Oct 2024 //
GLOBENEWSWIRE
MiNK Therapeutics To Present iNKT Cell Data At SITC 2024
04 Oct 2024 //
GLOBENEWSWIRE
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
MiNK Reports Second Quarter 2024 Results and Business Update
13 Aug 2024 //
GLOBENEWSWIRE
MiNK Therapeutics To Provide Q2 2024 Update And Financial Report
01 Aug 2024 //
GLOBENEWSWIRE
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
31 Jul 2024 //
GLOBENEWSWIRE
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
05 Jun 2024 //
GLOBENEWSWIRE
MiNK Presents AgenT-797 Activity In Severe ARDS At ATS
22 May 2024 //
GLOBENEWSWIRE
MiNK Reports First Quarter 2024 Results
14 May 2024 //
GLOBENEWSWIRE
MiNK Therapeutics Announces $5.8M Private Placement, Board Observer Appointed
13 May 2024 //
GLOBENEWSWIRE
MiNK Announces Promising Preclinical Activity of MiNK-215 at AACR
08 Apr 2024 //
GLOBENEWSWIRE
MiNK Reports Fourth Quarter and Year-End 2023 Results
21 Mar 2024 //
GLOBENEWSWIRE
MiNK to Provide Update and Fourth Quarter & Full Year 2023 Financial Report
07 Mar 2024 //
GLOBENEWSWIRE
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215
06 Mar 2024 //
GLOBENEWSWIRE
MiNK Therapeutics` AgenT-797 Shows Promising Results in Respiratory Distress
06 Feb 2024 //
GLOBENEWSWIRE
MiNK™s AgenT-797 Offers New Hope in Overcoming ICI Resistance
30 Jan 2024 //
GLOBENEWSWIRE
ImmunoScape and MiNK Collaborate to Accelerate Novel TCR Identification
20 Dec 2023 //
GLOBENEWSWIRE
MiNK Therapeutics Reports Third Quarter 2023 Results
09 Nov 2023 //
GLOBENEWSWIRE
MiNK Presents Long-Term Persistence of Allogeneic iNKT Cells
03 Nov 2023 //
GLOBENEWSWIRE
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
30 Oct 2023 //
GLOBENEWSWIRE
MiNK To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC
27 Sep 2023 //
GLOBENEWSWIRE
MiNK Therapeutics to Participate in September Investor Conferences
24 Aug 2023 //
GLOBENEWSWIRE
MiNK Therapeutics Reports Second Quarter 2023 Results
10 Aug 2023 //
GLOBENEWSWIRE
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
28 Jul 2023 //
GLOBENEWSWIRE
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
05 Jun 2023 //
GLOBENEWSWIRE
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Conference
22 May 2023 //
GLOBENEWSWIRE
MiNK`s Novel FAP-CAR-iNKT Presented at ASGCT
18 May 2023 //
GLOBENEWSWIRE
MiNK Reports Corporate Update and First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
MiNK Therapeutics to Report 1Q 2023 FYR & Corporate Update
27 Apr 2023 //
GLOBENEWSWIRE
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797)
18 Apr 2023 //
GLOBENEWSWIRE
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
30 Mar 2023 //
BUSINESSWIRE
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
21 Mar 2023 //
GLOBENEWSWIRE
MiNK to Present Data of allo-iNKT Cell Therapy in Solid Tumors
15 Mar 2023 //
GLOBENEWSWIRE
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
07 Mar 2023 //
GLOBENEWSWIRE
MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Conference
16 Feb 2023 //
GLOBENEWSWIRE
MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference
11 Jan 2023 //
GLOBENEWSWIRE
MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
17 Nov 2022 //
GLOBENEWSWIRE
MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline
10 Nov 2022 //
GLOBENEWSWIRE
MiNK unveils data on killer T cell therapy for ARDS, pending contract with DARPA
10 Nov 2022 //
ENDPTS
MiNK Therapeutics Reports Corporate Update and 3Q FYR
03 Nov 2022 //
GLOBENEWSWIRE
MiNK to Report Third Quarter 2022 Financial Results and Business Update
20 Oct 2022 //
GLOBENEWSWIRE
MiNK Selected for Five Presentations at Society Immunotherapy of Cancer’s (SITC)
05 Oct 2022 //
GLOBENEWSWIRE
MiNK Therapeutics to Host R&D Event November 10, 2022
05 Oct 2022 //
GLOBENEWSWIRE
MiNK Therapeutics to Participate at Upcoming Investor Conferences
31 Aug 2022 //
GLOBENEWSWIRE
